We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of ...

Shares sank 7.2% to $122.24, heading for the worst same-day percentage decrease since a 9.3% drop in June 2021, according to ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories, which makes the popular BinaxNow COVID-19 tests, expects significantly fewer sales of its COVID-19 tests in the fourth quarter compared with the rest of the year.

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

On the same day that United Airlines forecast stability, Abbott Labs warned investors to expect a $200 million hit.

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories first quarter profits eclipsed $2.4 billion thanks to a surge in sales of Covid-19 diagnostic tests as demand grew with the spread of the Omicron variant earlier this year.